ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1796

Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades

Elif Dincses1, Yesim Ozguler2, Didar Ucar3, Yilmaz Ozyazgan4, Serdal Ugurlu2, Gulen Hatemi2, Melike Melikoglu2, Sebahattin Yurdakul2, Hasan Yazici5 and Emire Seyahi2, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 5Istanbul Academic Hospital, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is some evidence that incident Behcet’s syndrome (BS) might be becoming less severe (1, 2). We compared clinical findings at presentation of BS patients registered in a large, long standing dedicated multidisciplinary outpatient clinic at 4 time points during a 40-years period.

Methods: There were 4 groups. Group 1 included patients registered in 1979- 1981, Group 2 those registered in 1990, Group 3 in 2000 and Group 4 in 2010. Only demographic and clinical findings at initial presentation were recorded on prepared forms.   

Results: As shown in Table 1, over 4 decades, male/female ratio decreases gradually. While mean age at presentation does not change, the median disease duration got shorter. Almost all clinical manifestations except genital ulcers and neurological involvement tended to decrease in frequency. This was also true when genders were separately analyzed. Importantly the severity of vascular and eye disease decreased (Table 2). The slope of vascular disease was more obvious.

Conclusion: Our observations support the notion that incident BS might be getting milder. There might be a list of explanations for this observation. 1. It might be a true biological phenomenon due to changing environmental causes. In this line the significant decrease in papulopustular lesions could be due to a more sanitary environment while the rather unchanging frequency of neurologic involvement might be its possible independence from the environment. 2. It might be that the awareness of BS is increasing and we are recognizing less severe cases earlier. 3. Another explanation might be the more effective treatment these patients received before they were referred which was not specifically sought in this survey.

References:

1.       Yoshida A, et al. Comparison of patients with Behçet’s disease in the 1980s and 1990s. Ophthalmology. 2004.

2.       Cingu AK, et al. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012.

Table 1. Initial demographic and clinical characteristics of cohorts

Group 1

1979-81 cohort n=211

Group 2

1990 cohort

n=170

Group 3

2000 cohort

n=225

Group 4

2010 cohort

n= 270

P

Male /Female

140/71

110/ 60

142/ 83

150/ 120

0.069

Male/Female ratio

1.97

1.83

1.71

1.25

Mean age at disease onset

31.5 ± 8.3

30.9 ± 9.0

30.7± 9.3

32.3 ± 9.6

NS

Median disease duration

2.5 [1.0-6.0]

2.0 [1.0-5.0]

1 [0.5-3]

1 [0.6-4]

0.06

Mucocutaneous inv. , n (%)

     Genital ulceration

187 (88.6)

137 (80.6)

184 (81.7)

220 (81.4)

NS

     Papulopustular lesion

174 (82.5)

130 (76.5)

187 (83)

185 (68.5)

<0.001

     Erythema nodosum

132 (62.6)

88 (51.8)

101 (44.8)

112 (41.4)

<0.001

Ocular involvement, n (%)

107 (50.7)

107 (62.4)

97 (43.1)

129 (47.7)

0.001

Vascular involvement, n (%)

49 (23.2)

29 (17.0)

41 (18.2)

31 (11)

0.008

Large vessel involvement, n (%)

21 (42.9)

11 (38.0)

13 (31.7)

7 (22.5)

<0.001

Neurologic involvement, n (%)

7 (3.3)

6 (3.5)

5 (2.2)

10 (3.7)

NS

Arthritis, n (%)

79 (37.4)

37 (21.8)

53 (23.6)

56 (20.7)

<0.001

 

Table 2. Severity of ocular involvement at presentation

Ocular involvement

1979-81 cohort

n =107

1990 cohort

n=106

2000 cohort

n=97

2010 cohort

n= 129

p

Visual acuity < 0.1 in bilateral eyes, n (%)

17 (15.7)

8 (7.5)

6 (6.5)

9   (6.9)

0.03*

Visual acuity < 0.1 in unilateral eye, n (%)

23 (21.3)

19 (17.9)

18 (19.7)

22 (17)

0.39**

Visual acuity > 0.5 in bilateral eyes

39 (36.1)

54(55.6)

55 (60.4)

73 (56.6)

0.002**

*Cohort 1 vs 4 and Cohort 1 vs 3; **Cohort 1 vs 4


Disclosure: E. Dincses, None; Y. Ozguler, None; D. Ucar, None; Y. Ozyazgan, None; S. Ugurlu, None; G. Hatemi, None; M. Melikoglu, None; S. Yurdakul, None; H. Yazici, None; E. Seyahi, None.

To cite this abstract in AMA style:

Dincses E, Ozguler Y, Ucar D, Ozyazgan Y, Ugurlu S, Hatemi G, Melikoglu M, Yurdakul S, Yazici H, Seyahi E. Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/retrospective-analysis-of-initial-presentation-findings-of-behcets-syndrome-throughout-4-decades/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retrospective-analysis-of-initial-presentation-findings-of-behcets-syndrome-throughout-4-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology